This patent seems to cover the preservation of a kidney, despite its title. It may be that preservation is achieved through endogenous stem cell differentiation of kidney epithelium. The patent has one claim covering a method of preserving a kidney by contacting the kidney with a ligand for gp130 receptor (ie LIF, a cardiotrophin, a ciliary neuronotrophic factor, an interleukin-6), and a growth factor (TGF.alpha., a FGF-2, a FGF-9, a TIMP-1, TIMP-2 ).
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.